QLINEA.ST
Q-linea AB (publ) [QLINEA.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
QLINEA.ST Stock Summary
In the News
QLINEA.ST Financial details
Company Rating
-
Market Cap
245.94M
Income
-228.94M
Revenue
4.44M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
127
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-0.35
Forward P/E
-
PEG
0.08
P/S
96.61
P/B
0.35
P/C
-
P/FCF
-1.6
Quick Ratio
5.11
Current Ratio
8.31
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.33
EPS next Y
-
EPS next Q
-
EPS this Y
-63.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-14.94%
Revenue last 5Y
34.6%
Revenue Q/Q
-97.97%
EPS Q/Q
-17.86%
-
-
-
-
SMA20
-
SMA50
-89.74%
SMA100
-96.52%
Inst Own
-
Inst Trans
-
ROA
-85%
ROE
-180%
ROC
-0.9%
Gross Margin
-97%
Oper. Margin
-5334%
Profit Margin
-5553%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.0-10.3
52W High
-99.64%
52W Low
-98.2%
RSI
34.37
Rel Volume
71.02
Avg Volume
173.83K
Volume
12.35M
Perf Week
-11.98%
Perf Month
-11.76%
Perf Quarter
-98.54%
Perf Half Y
-98.56%
-
-
-
-
Beta
1.095
-
-
Volatility
0%, 0%
Prev Close
-0.28%
Price
0.036
Change
-5.01%
Company Profile
- Volume Average 173.83K
- Market Capitalization 245.94M
- Employee 127
- CEO Mr. Stuart Gander
- Headquarters Uppsala,SE
- IPO Date 2018-12-07
-
Website
https://www.qlinea.com 
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
